<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CHLORPROPAMIDE</span><br/>(klor-proe'pa-mide)<br/><span class="topboxtradename">Apo-Chlorpropamide <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename"> Chloronase, </span><span class="topboxtradename">Diabinese, </span><span class="topboxtradename">Glucamide, </span><span class="topboxtradename">Novopropamide <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification"> hormone and synthetic substitute</span>; <span class="classification">antidiabetic sulfonylurea</span><br/><b>Prototype: </b>Glyburide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 250 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Longest-acting first-generation sulfonylurea compound, structurally and pharmacologically related to tolbutamide. Although
         a sulfonamide derivative, it has no antiinfective activity. Lowers blood glucose by stimulating beta cells in pancreas to
         synthesize and release endogenous insulin. May potentiate available antidiuretic hormone (ADH) secretion, a property not shared
         by other sulfonylureas.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antidiabetic effect is due to the ability of the drug to stimulate the beta cells of the pancreas to manufacture and release
         insulin. Therapeutic effectiveness is indicated by HbA<sub>1c</sub> levels &gt;7%.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderately severe, stable non-insulin-dependent diabetes mellitus (type 2) in patients who cannot be controlled by
         diet alone and who do not have complications of diabetes.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Neurogenic diabetes insipidus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to sulfonylureas and to sulfonamides; diabetes complicated by severe infection; acidosis; severe renal,
         hepatic, or thyroid insufficiency. Safe use during pregnancy (category C), in nursing mothers, and in children not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adult patients, Addison's disease, CHF, and hepatic porphyria.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Antidiabetic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initial: 100250 mg/d with breakfast, adjust by 50125 mg/d q35d until glycemic control is achieved, up to
               750 mg/d<br/><br/><span class="indicationtitle">Antidiuretic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100250 mg/d, may adjust q23d up to 500 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give as a single morning dose with breakfast. To reduce GI adverse effects, drug may be prescribed as 2 or 3 doses and taken
            with meals.
         </li>
<li>Store below 40° C (104° F), preferably at 15°30° C (59°86° F) in a tightly closed
            container, unless otherwise directed.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Flushing, photosensitivity, alcohol intolerance. <span class="typehead">GI:</span> GI distress, anorexia, nausea, diarrhea, constipation, cholestatic jaundice. <span class="typehead"> Hematologic:</span> Leukopenia, thrombocytopenia, <span class="speceff-life">agranulocytosis</span>. <span class="typehead">Metabolic:</span>
<span class="speceff-life">Hypoglycemia</span>, antidiuretic effect (SIADH), dilutional hyponatremia, water intoxication. <span class="typehead">CNS:</span> Drowsiness, muscle cramps, weakness, paresthesias. <span class="typehead">Skin:</span> Rash, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  Adverse effects of <span class="classification">oral anticoagulants</span>, <b>phenytoin,</b>
<span class="classification">salicylates</span>, <span class="classification">nsaids</span> may be increased along with those of chlorpropamide; <span class="classification">thiazide diuretics</span> may increase blood sugar; <b>alcohol</b> produces disulfiram reaction; <b>probenecid,</b>
<span class="classification">mao inhibitors</span> may increase hypoglycemic effects. <span class="typehead">Herbal:</span>
<b>Garlic,</b>
<b>ginseng</b> may increase hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 1 h. <span class="typehead">Peak:</span> 36 h. <span class="typehead">Distribution:</span> Highly protein bound; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 8090% excreted in urine in 96 h. <span class="typehead">Half-Life:</span> 36 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness: Indicated by HbA<sub>1c</sub> levels &gt;7%.
         </li>
<li>Monitor blood and urine glucose to determine effectiveness of glycemic control.</li>
<li>Lab tests: Periodic fasting and postprandial blood glucose; HbA<sub>1c</sub> every 3 mo; baseline and periodic hematologic and hepatic studies are advisable, particularly in patients receiving high
            doses. A CBC should be performed if symptoms of anemia appear.
         </li>
<li>Report dizziness, shortness of breath, malaise, fatigue.</li>
<li>Monitor for S&amp;S of hypoglycemia (see Appendix F).</li>
<li>Monitor I&amp;O ratio and pattern: Infrequently, chlorpropamide produces an antidiuretic effect, with resulting severe hyponatremia,
            edema, and water intoxication. If fluid intake far exceeds output and edema develops (weight gain), report to the physician.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report hypoglycemic episodes to physician. Because chlorpropamide has a long half-life, hypoglycemia can be severe, although
            onset is not as fast or as dramatic as with use of insulin.
         </li>
<li>Report any of the following immediately to physician: skin eruptions, malaise, fever, or photosensitivity. Immediately report
            these symptoms to physician. A change to another hypoglycemic agent may be indicated.
         </li>
<li>Do not self-dose with OTC drugs unless approved or prescribed by the physician.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>